...
首页> 外文期刊>Antioxidants and redox signalling >Inhibition of Lung Cancer by 2-Methoxy-6-Acetyl-7-Methyljuglone Through Induction of Necroptosis by Targeting Receptor-Interacting Protein 1
【24h】

Inhibition of Lung Cancer by 2-Methoxy-6-Acetyl-7-Methyljuglone Through Induction of Necroptosis by Targeting Receptor-Interacting Protein 1

机译:通过靶向受体相互作用蛋白1,通过诱导粪便抑制2-甲氧基-6-乙酰乙酰-7-甲基juglone抑制肺癌

获取原文
获取原文并翻译 | 示例

摘要

Aims: Most chemotherapeutic agents exploit apoptotic signaling to trigger cancer cell death, which frequently results in drug resistance. Necroptosis, a nonapoptotic form of regulated cell death, offers an alternative strategy to eradicate apoptosis-resistant cancer cells. We previously reported a natural necroptosis inducer 2-methoxy-6-acetyl-7-methyljuglone (MAM) in A549 lung cancer cells. The current study is designed to investigate the detailed necroptotic signaling and its cytotoxicity on drug-resistant cancer cells. Furthermore, in vivo anticancer effects were also evaluated in nude mice model. Results: MAM directly targets receptor-interacting protein 1 (RIP1) kinase in A549 and H1299 cells, which is responsible for reactive oxygen species (ROS, mainly hydrogen peroxide) generation. A positive feedback loop between calcium (Ca2+) and c-Jun N-terminal kinase (JNK) occurred following ROS generation, leading to lysosomal membrane permeabilization and mitochondrial dysfunction. MAM showed similar cytotoxic potency toward cisplatin-resistant A549 (A549/Cis) cells by inducing necroptosis as confirmed by the protective effect of 7-Cl-O-Nec-1 (Nec-1s) and by the morphological characteristics obtained via transmission electron microscopy. Interestingly, tumor necrosis factor alpha (TNF alpha) was not involved in this process. Intraperitoneal injection of MAM significantly suppressed tumor growth in A549 tumor xenograft without significant body weight loss and multiorgan toxicities. Innovation and Conclusion: Our findings demonstrate that MAM induces necroptosis in A549 and H1299 lung cancer cells by targeting RIP1 kinase and ROS in a TNF alpha-independent manner. MAM kills A549/Cis cells with similar potency through induction of necroptosis. MAM shows anticancer effect in animal model. The present study raises the therapeutic possibility and strategy to combat cancer by the induction of necroptosis.
机译:目的:大多数化学治疗剂利用凋亡信号传导,以触发癌症细胞死亡,这通常导致耐药性。 Necroptis,一种缺乏凋亡的细胞死亡形式,提供了根除凋亡抗性癌细胞的替代策略。我们之前报道了A549肺癌细胞中的天然虐和诱导剂2-甲氧-6-乙酰-7-甲基juglone(MAM)。目前的研究旨在探讨耐药性癌细胞上的细微抗病传统信号及其细胞毒性。此外,在裸鼠模型中还评估了体内抗癌效果。结果:MAM直接靶向A549和H1299细胞中的受体相互作用蛋白1(RIP1)激酶,其负责反应性氧(ROS,主要过氧化氢)产生。在ROS产生后,钙(Ca2 +)和C-Jun N-末端激酶(JNK)之间的阳性反馈环发生,导致溶酶体膜透化和线粒体功能障碍。 MAM通过通过诱导7-CL-O-NEC-1(NEC-1S)的保护作用和通过透射电子显微镜获得的形态特征来诱导虐待症,通过诱导DEClatin抗性A549(A549 / CIS)细胞对顺铂抗性A549(A549 / CIS)细胞相似的细胞毒性效力。通过通过透射电子显微镜获得的形态学特性。有趣的是,肿瘤坏死因子α(TNF alpha)没有参与该过程。腹膜内注射MAM显着抑制A549肿瘤异种移植物中的肿瘤生长,而无明的体重减轻和多功能毒性。创新和结论:我们的研究结果表明,通过以TNFα-独立的方式靶向RIP1激酶和ROS,MAM在A549和H1299肺癌细胞中诱导坏死。 MAM通过诱导死亡症杀死具有类似效力的A549 /顺式细胞。 MAM显示动物模型中的抗癌效果。目前的研究提高了对抗病症诱导癌症的治疗可能性和策略。

著录项

  • 来源
    《Antioxidants and redox signalling 》 |2019年第2期| 共16页
  • 作者单位

    Univ Macau Inst Chinese Med Sci State Key Lab Qual Res Chinese Med Ave Univ Taipa Macao;

    Univ Macau Inst Chinese Med Sci State Key Lab Qual Res Chinese Med Ave Univ Taipa Macao;

    Univ Macau Inst Chinese Med Sci State Key Lab Qual Res Chinese Med Ave Univ Taipa Macao;

    Univ Macau Inst Chinese Med Sci State Key Lab Qual Res Chinese Med Ave Univ Taipa Macao;

    China Acad Chinese Med Sci Natl Resource Ctr Chinese Mat Med State Key Lab Breeding Base Daodi;

    Univ Macau Inst Chinese Med Sci State Key Lab Qual Res Chinese Med Ave Univ Taipa Macao;

    Univ Macau Inst Chinese Med Sci State Key Lab Qual Res Chinese Med Ave Univ Taipa Macao;

    Univ Macau Inst Chinese Med Sci State Key Lab Qual Res Chinese Med Ave Univ Taipa Macao;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 基础医学 ;
  • 关键词

    MAM; RIP1; necroptosis; drug resistance; cancer;

    机译:妈妈;RIP1;坏凋亡;耐药;癌症;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号